LivaNova PLC is a global medical technology company operating in two primary segments: Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment designs, manufactures, and sells products for cardiopulmonary bypass (CPB) procedures, including heart-lung machines (HLMs), oxygenators, autotransfusion systems, and perfusion tubing. Key products in this segment include the Essenz Perfusion System and the Inspire range of oxygenators, which serve neonatal, pediatric, and adult patients undergoing cardiac surgeries such as coronary artery bypass grafting and valve repairs. The Neuromodulation segment develops implantable devices for neurological conditions, specifically drug-resistant epilepsy (DRE) and treatment-resistant depression (DTD). Its flagship product, the VNS Therapy System, stimulates the vagus nerve to reduce seizures and manage depression, with models including Demipulse, AspireSR, SenTiva, and SenTiva Duo. The company is also developing the aura6000 System for obstructive sleep apnea (OSA) through its subsidiary ImThera. LivaNova serves patients, healthcare professionals, and healthcare systems worldwide, with products approved in various jurisdictions including the U.S. and the EU.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage livanova.com
Sector Healthcare IR page investor.livanova.com
Tags
cardiopulmonary bypass, neuromodulation, epilepsy, treatment-resistant depression, obstructive sleep apnea, heart-lung machines, oxygenators, autotransfusion, vagus nerve stimulation, implantable pulse generators, Essenz Perfusion System, Inspire, VNS Therapy System, Demipulse, AspireSR, SenTiva, SenTiva Duo, aura6000 System, ImThera
Press page —

Metrics

Valuation  
Market cap $ 5.008B
Market cap (USD) $ 5.008B
P/E 25.83
PEG —
P/BV 3.65
P/S 3.32
P/OCF 21.05
P/FCF 38.81
Dividend yield —
Turnover / mcap —
Returns  
ROE -19.2%
ROI -15.4%
ROIC 9.5%
Profit margin -17.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 21.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 43
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 1.388B 1.253B 1.154B 1.022B 1.035B 934.241M 1.084B 1.107B 1.012B 1.214B
Net profit -242.471M 63.234M 17.546M -86.246M -135.818M -345.008M -155.176M -189.399M -25.089M -62.789M
Free cash flow 173.29M 135.931M 39.933M 43.404M 77.066M -114.446M -115.833M 82.492M 57.232M 53.667M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 61.53 46.31 51.74 55.54 87.43 66.21 75.43 91.47 79.92 44.97
Price performance 12m 0.33 -0.1 -0.07 -0.36 0.32 -0.12 -0.18 0.14 0.78 -0.24

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 276M 282M 256M 258M 184M 185M 183M 215M 193M 216M
↳ YoY growth +1.2% +2.3% -9.2% +0.6% -28.5% +0.5% -1.2% +17.5% -10.2% +11.8%
↳ 5y CAGR -7.5% -7.6% -8.3% -3.4% -5.6% +3.2%
Borrowings, current (USD) 47.7M 25.8M 23.3M 73.2M 8.38M 227M 20.9M 17.5M 77.3M 30.9M
Borrowings, non-current (USD) 75.2M 62M 140M 260M 642M 9.85M 518M 569M 550M 345M
Lease liabilities (USD) — — 0.00 57.1M 53.5M 47.2M 38.9M 53.8M 49.1M 57.1M
Cash and deposits (USD) 39.8M 93.6M 47.2M 61.1M 253M 208M 214M 267M 429M 636M
Intangible assets (USD) 609M 446M 412M 608M 438M 400M 369M 261M 237M 230M
Right-of-use assets (USD) — — 0.00 54.4M 50.5M 40.6M 35.8M 50.8M 46.8M 55.5M
Net debt (borrowings + leases - cash) (USD) 83.1M -5.81M 116M 330M 451M 76M 364M 373M 247M -202M
Cash flow detail
Operating cash flow (USD) 90.2M 91.3M 120M -91.1M -79.4M 103M 69.9M 74.9M 183M 254M
Purchases of property, plant and equipment (USD) -36.5M -34.1M -38M -24.7M -35M -25.5M -26.5M -35M -47.1M -81.1M
Purchases of intangible assets (USD) -1.88M -1.17M -809,000 -3.29M 0.00 — — — — —
Change in receivables (cash effect) (USD) -16.4M -48.9M 21.2M -5.32M 58.8M -15.7M -4.81M -28.9M 11.1M -10.7M
Change in inventories (cash effect) (USD) 26.7M 7.19M -10.6M -10.6M 1.4M 4.48M -25.7M -28.5M -6.76M -5.29M
Share buybacks (cash effect) (USD) -54.5M 0.00 -50M 0.00 0.00 — — — — —
Interest paid (cash effect) (USD) -7.37M -7.51M -9,278 -15.8M -28.6M -32.6M -19M -36.9M -38.9M -31.1M
Income taxes paid (cash effect) (USD) -47.8M -39M -26,000 -2.01M -7.49M 13.6M -1.22M 1.62M -15.9M -29.4M
Share-based compensation (USD) 19.6M 19.1M 26.9M 32.6M 35.1M 40.6M 44.8M 36.4M 33.9M 36.3M
Operating cash flow before change in receivables (USD) 107M 140M 99.3M -85.8M -138M 118M 74.7M 104M 172M 265M
Free cash flow (OCF - PPE - intangibles) (USD) 51.8M 57.2M 82.5M -119M -114M 77.1M 43.4M 39.9M 136M 173M
Income detail
Research and development expense (USD) 122M 110M 146M 150M 153M 183M 156M 194M 183M 186M
↳ 5y CAGR +8.4% +7.3% +5.8% +4.0% +4.0%
Total comprehensive income (USD) -77M 88.7M -259M -150M -298M -171M -127M 37.8M 10.9M -155M
Comprehensive income to owners (USD) -77M 88.7M -259M -150M -298M -171M -127M 37.8M 10.9M -155M
Reported Mar 1, 2017 Mar 2, 2020 Mar 2, 2020 Mar 2, 2020 Mar 1, 2021 Mar 1, 2022 Feb 27, 2023 Feb 29, 2024 Feb 25, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

LivaNova Reports Third-Quarter 2026 Results 177.4 KB

– Delivered 9.9% reported and 10.0% constant-currency revenue growth

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Achieved a key milestone in scaling oxygenator production capacity with the operational launch of a dedicated manufacturing line

GLOUCESTER, England--(BUSINESS WIRE)--Nov. 4, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104266833/en/

Financial Summary and Highlights(1)

  • Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period

  • Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per share of $1.23

  • Third-quarter net cash provided by operating activities of $73.7 million and adjusted free cash flow of $55.8 million

  • Raised full-year 2026 revenue growth range by 100 basis points to 9% to 10% on a constant-currency basis. Raised full-year 2026 adjusted diluted earnings per share range by $0.10 at midpoint to $4.40 to $4.50. Maintained full-year 2026 adjusted free cash flow range of $140 million to $160 million

  • Achieved operational production on previously announced new oxygenator manufacturing line, representing an important milestone in expanding production capacity to address strong customer demand

  • In October 2026, the American Medical Association CPT® Editorial Panel announced the establishment of new Category I Current Procedural Terminology (CPT®) codes that include LivaNova’s proximal hypoglossal nerve stimulation therapy for the treatment of moderate to severe obstructive sleep apnea, with an expected effective date of January 1, 2028

  • In October 2026, announced the publication of the full 36-month results from the CORE-VNS study, the largest prospective, international study evaluating contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy, in Neuromodulation demonstrating a 76% median reduction in seizure frequency and a durable clinical benefit

| | | |

| (1) | Constant-currency percent change, adjusted diluted earnings per share, and adjusted free cash flow are non-GAAP measures. Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. For an explanation of these and other non-GAAP measures used in this news release, see the section entitled "Use of Non-GAAP Financial Measures." For reconciliations of certain non-GAAP measures, see the tables that accompany this news release. As discussed in the section entitled "Use of Non-GAAP Financial Measures" below, the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Accordingly, the Company is unable to reconcile forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts. |

“Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “We also made meaningful progress against key milestones, positioning us to address significant market demand while expanding patient access to care. Our updated 2026 guidance reflects confidence across the portfolio as we advance our strategic priorities, drive innovation to address important unmet patient needs, and remain focused on delivering long-term shareholder value.”

Third-Quarter 2026 Results

The following table summarizes net revenue by segment (in millions):

| | | Three Months Ended September 30, | | % Change | | Constant-Currency % Change |

| | | 2026 | | 2025 | | |

| Cardiopulmonary | | $225.3 | | $203.2 | | 10.9 % | | 10.9 % |

| Neuromodulation | | 166.1 | | 149.5 | | 11.1 % | | 11.2 % |

| Other Revenue (1) | | 1.7 | | 5.0 | | (65.7) % | | (65.2) % |

| Total Company | | $393.1 | | $357.8 | | 9.9 % | | 10.0 % |

| (1) | Other revenue” includes rental and site services income not allocated to segments. In addition, for 2025, “Other revenue” includes $3.1 million from a reduction in the reserve associated with the Italian MedTech payback measure related to product sales of previously divested businesses. |

| * Numbers may not add precisely due to rounding. |

Third-quarter 2026 Cardiopulmonary revenue increased 10.9% on a reported basis and 10.9% on a constant-currency basis versus the third quarter of 2025 with growth across all regions, driven by strong consumables demand and Essenz™ Perfusion System sales, as well as favorable realized price.

Third-quarter 2026 Neuromodulation revenue increased 11.1% on a reported basis and 11.2% on a constant-currency basis versus the third quarter of 2025 with growth across all regions, driven by higher volume and favorable realized price.

Earnings Analysis

On a U.S. GAAP basis, third-quarter 2026 operating income was $28.4 million, as compared to operating income of $54.0 million for the third quarter of 2025. Adjusted operating income for the third quarter of 2026 was $92.3 million, as compared to adjusted operating income of $80.4 million for the third quarter of 2025.

On a U.S. GAAP basis, third-quarter 2026 diluted earnings per share was $0.11 as compared to diluted earnings per share of $0.49 in the third quarter of 2025. Third-quarter 2026 adjusted diluted earnings per share was $1.23, as compared to adjusted diluted earnings per share of $1.11 in the third quarter of 2025.

Full-Year 2026 Guidance

LivaNova now expects full-year 2026 revenue to grow between 9% and 10% (versus 8% and 9% prior) on a constant-currency basis. Foreign currency is expected to be a tailwind of approximately 1% based on current exchange rates, consistent with prior guidance.

Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.40 to $4.50 (versus $4.30 to $4.40 prior), assuming a share count of approximately 56 million for full-year 2026. In 2026, the Company estimates adjusted free cash flow in the range of $140 million to $160 million, consistent with prior guidance.

As discussed in the section entitled “Use of Non-GAAP Financial Measures” below, the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Accordingly, the Company is unable to reconcile the forward-looking non-GAAP financial measures included in this section to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts.

Audiocast and Conference Call Instructions

The Company will host a live audiocast at 1 p.m. London time (8 a.m. Eastern Standard Time) on Wed., November 4, 2026 that will be accessible at www.livanova.com/events. Listeners should register in advance and log on approximately 10 minutes early to ensure proper setup. To listen to the conference call by telephone, dial +1 833 461 5787 (if dialing from within the U.S.) or +1 585 542 9983 (if dialing from outside the U.S.). The conference call meeting ID is 495924914. Within 24 hours of the audiocast, a replay will be available at www.livanova.com/events, where it will be archived and accessible for approximately 90 days.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience with a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. With its registered office in the United Kingdom, approximately 3,300 employees, and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Use of Non-GAAP Financial Measures

To supplement financial measures presented in accordance with generally accepted accounting principles in the United States (U.S. GAAP or GAAP), management has disclosed certain additional measures not presented in accordance with GAAP known as “non-GAAP financial measures” or “adjusted financial measures.” Company management uses these non-GAAP measures to monitor the Company’s operational performance and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, operational performance measures as prescribed by GAAP.

In this news release, the Company refers to revenue and percentage change in revenue on a comparable, constant-currency basis. Company management believes that these non-GAAP measures provide a useful way to evaluate the revenue performance of LivaNova and to compare the revenue performance of current periods to prior periods on a consistent basis. Constant-currency percent change measures the change in revenue between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.

LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net revenue growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted diluted earnings per share guidance excludes items such as, but not limited to, changes in fair value of certain derivatives and contingent consideration arrangements and asset impairment charges that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for adjusted free cash flow is net cash provided by operating activities. Adjusted free cash flow is defined as net cash provided by operating activities less cash used for the purchase of property, plant, and equipment excluding the impact of 3T litigation settlement payments, cybersecurity incident insurance proceeds, SNIA environmental liability and related financing costs, contingent consideration payments classified within operating cash flows, and gains related to dividends received from investments and further adjusted as needed for other charges, expenses, or gains that may not be indicative of the Company’s operational performance. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, the ultimate outcome of legal proceedings, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of derivatives, and contingent consideration arrangements, asset impairment charges and the tax impact of the aforementioned items, tax law changes, or other tax matters. Accordingly, the Company does not reconcile non-GAAP financial measures on a forward-looking basis as it is impractical to do so without unreasonable effort.

Adjusted financial measures such as adjusted cost of sales, adjusted gross profit, adjusted selling, general, and administrative expense, adjusted research and development expense, adjusted other operating expense, adjusted operating income, adjusted income before income tax, adjusted income tax expense, adjusted net income, and adjusted diluted earnings per share are measures that LivaNova generally uses to facilitate management review of the operational performance of the company, to serve as a basis for strategic planning, and in the design of incentive compensation plans. Additionally, the Company uses the non-GAAP liquidity measure adjusted free cash flow. The Company believes that the presentation of these adjusted financial measures allows investors to evaluate the Company’s operational performance for different periods on a more comparable and consistent basis, and with other medical technology companies by adjusting for items that are not related to the operational performance of the Company or incurred in the ordinary course of business.

Safe Harbor Statement

Certain statements in this news release, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects, or future events, and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. Generally, forward-looking statements can be identified by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and shareholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this news release, and include, but are not limited to, the following risks and uncertainties: risks associated with doing business globally, including volatility in the global market and worldwide economic conditions; adverse changes in export and import costs and other trade restrictions as well as uncertainty over global tariffs; risks relating to supply chain pressures; failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption; costs of complying with privacy and security of personal information requirements and laws; changes in technology, including the development of superior or alternative technology or devices by competitors and/or competition from providers of alternative medical therapies; risks related to AI integration and regulation; failure of investments, alliances, supply agreements, acquisitions, or divestitures to achieve expected returns; failure to maintain appropriate working relationships with healthcare professionals to aid in the continuing development of products; the risk of quality issues and the impacts thereof; risks relating to recalls, replacement of inventory, enforcement actions, or product liability claims; failure to comply with, or changes in, laws, regulations, or administrative practices affecting government regulation of the Company’s products; failure to retain talent, maintain an effective succession plan, and negotiate successfully with local works councils; failure to obtain or maintain approvals, clearance, or reimbursement in relation to the Company’s products; unfavorable results from clinical studies or failure to meet milestones; global healthcare policy changes that may lead to restricted access and pricing as well as payback requirements and limited reimbursement; failure to comply with rules relating to healthcare goods and services as well as anti-bribery laws; the unfavorable impact of pending or existing climate change; product liability, intellectual property, shareholder-related, environmental-related, income tax, and other litigation, disputes, losses, and costs, including in the case of the Company’s 3T Heater-Cooler litigation; risks associated with environmental laws and regulations as well as environmental liabilities, violations, and litigation, including in the case of Saluggia and SNIA; failure to protect the Company’s proprietary intellectual property; changes in tax laws and regulations, including exposure to additional income tax liabilities; risks relating to the Company’s indebtedness; risks associated with potential government shutdowns; the potential for impairments of intangible assets, goodwill, and other long-lived assets; risks associated with public health crises; risks associated with shareholder activism; effectiveness of the Company’s internal controls over financial reporting; changes in the Company’s profitability and/or failure to manage costs and expenses; fluctuations in future quarterly operating results and/or variations in revenue and operating expenses relative to estimates; and other unknown or unpredictable factors that could harm the Company’s financial performance.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the U.S. Securities and Exchange Commission by LivaNova.

Readers are cautioned not to place undue reliance on the Company’s forward-looking statements, which speak only as of the date of this news release. The Company undertakes no obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If LivaNova updates one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.

VNS Therapy and Essenz are trademarks of LivaNova USA, Inc.

| LIVANOVA PLC |

| NET REVENUE - UNAUDITED |

| (In millions) |

| | | Three Months Ended September 30, |

| | | 2026 | | 2025 | | % Change | | Constant-Currency % Change |

| Cardiopulmonary | | | | | | | | |

| U.S. | | $80.4 | | $71.9 | | 11.8 % | | 11.8 % |

| Europe (1) | | 57.1 | | 50.1 | | 14.0 % | | 15.9 % |

| Rest of World (1) | | 87.8 | | 81.2 | | 8.1 % | | 7.1 % |

| | | 225.3 | | 203.2 | | 10.9 % | | 10.9 % |

| Neuromodulation | | | | | | | | |

| U.S. | | 130.7 | | 118.4 | | 10.4 % | | 10.4 % |

| Europe (1) | | 16.6 | | 14.5 | | 14.4 % | | 15.5 % |

| Rest of World (1) | | 18.8 | | 16.6 | | 13.0 % | | 12.9 % |

| | | 166.1 | | 149.5 | | 11.1 % | | 11.2 % |

| Other revenue (2) | | 1.7 | | 5.0 | | (65.7) % | | (65.2) % |

| Total Company | | | | | | | | |

| U.S. | | 211.1 | | 190.4 | | 10.9 % | | 10.9 % |

| Europe (1) | | 73.7 | | 67.7 | | 8.8 % | | 10.5 % |

| Rest of World (1) | | 108.3 | | 99.6 | | 8.7 % | | 7.9 % |

| | | $393.1 | | $357.8 | | 9.9 % | | 10.0 % |

| (1) | “Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates. |

| (2) | “Other revenue” includes rental and site services income not allocated to segments. In addition, for 2025, “Other revenue” includes $3.1 million from a reduction in the reserve associated with the Italian MedTech payback measure related to product sales of previously divested businesses. |

| * Numbers may not add precisely due to rounding. |

| LIVANOVA PLC |

| NET REVENUE - UNAUDITED |

| (In millions) |

| | | Nine Months Ended September 30, |

| | | 2026 | | 2025 | | % Change | | Constant-Currency % Change |

| Cardiopulmonary | | | | | | | | |

| U.S. | | $222.5 | | $204.0 | | 9.0 % | | 9.0 % |

| Europe (1) | | 176.3 | | 143.6 | | 22.8 % | | 19.1 % |

| Rest of World (1) | | 256.7 | | 231.2 | | 11.1 % | | 9.0 % |

| | | 655.5 | | 578.8 | | 13.3 % | | 11.5 % |

| Neuromodulation | | | | | | | | |

| U.S. | | 372.7 | | 344.0 | | 8.4 % | | 8.4 % |

| Europe (1) | | 54.8 | | 47.4 | | 15.5 % | | 11.4 % |

| Rest of World (1) | | 57.4 | | 48.7 | | 17.8 % | | 15.6 % |

| | | 484.9 | | 440.1 | | 10.2 % | | 9.5 % |

| Other revenue (2) | | 5.6 | | 8.2 | | (32.0) % | | (34.4) % |

| Total Company | | | | | | | | |

| U.S. | | 595.2 | | 548.1 | | 8.6 % | | 8.6 % |

| Europe (1) | | 231.1 | | 194.2 | | 19.0 % | | 15.3 % |

| Rest of World (1) | | 319.7 | | 284.9 | | 12.2 % | | 10.1 % |

| | | $1,146.0 | | $1,027.1 | | 11.6 % | | 10.3 % |

| (1) | “Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates. |

| (2) | “Other revenue” includes rental and site services income not allocated to segments. In addition, for 2025, “Other revenue” includes $3.1 million from a reduction in the reserve associated with the Italian MedTech payback measure related to product sales of previously divested businesses. |

| * Numbers may not add precisely due to rounding. |

| LIVANOVA PLC AND SUBSIDIARIES | | |

| CONDENSED CONSOLIDATED STATEMENTS OF INCOME - UNAUDITED |

| (In millions, except for per share amounts) | | |

| | | | | |

| | | Three Months Ended September 30, |

| | | 2026 | | 2025 |

| Net revenue | | $393.1 | | $357.8 |

| Cost of sales | | 128.1 | | 112.9 |

| Gross profit | | 265.1 | | 244.9 |

| Operating expenses: | | | | |

| Selling, general, and administrative | | 154.9 | | 138.5 |

| Research and development | | 47.7 | | 48.6 |

| Other operating expense | | 34.0 | | 3.7 |

| Operating income | | 28.4 | | 54.0 |

| SNIA environmental liability expense | | — | | (1.7) |

| Interest expense | | (8.0) | | (10.9) |

| Foreign exchange and other income/(expense) | | 26.3 | | (7.5) |

| Income before income tax | | 46.8 | | 33.9 |

| Income tax expense | | 12.4 | | 7.1 |

| Loss from equity method investments | | (0.1) | | — |

| Net income | | $34.3 | | $26.8 |

| | | | | |

| Earnings per share: (1) | | | | |

| Basic | | $0.62 | | $0.49 |

| Diluted | | $0.11 | | $0.49 |

| | | | | |

| Weighted average shares outstanding: | | | | |

| Basic | | 55.1 | | 54.6 |

| Diluted | | 57.4 | | 55.2 |

| (1) | For additional details, refer to the computation of basic and diluted earnings (loss) per share further in this news release. |

| * Numbers may not add precisely due to rounding. |

| Adjusted Financial Measures (in millions, except for per share amounts) - Unaudited |

| | | |

| | | Three Months Ended September 30, |

| | | 2026 | | 2025 |

| Adjusted SG&A | | $135.7 | | $122.8 |

| Adjusted R&D | | 44.7 | | 45.0 |

| Adjusted operating income | | 92.3 | | 80.4 |

| Adjusted net income | | 70.7 | | 61.4 |

| Adjusted diluted earnings per share | | $1.23 | | $1.11 |

| Statistics (as a % of net revenue, except for income tax rate) - Unaudited |

| | | | | |

| | | GAAP Three Months Ended September 30, | | Adjusted Three Months Ended September 30, |

| | | 2026 | | 2025 | | 2026 | | 2025 |

| Gross profit | | 67.4 % | | 68.4 % | | 69.3 % | | 69.4 % |

| SG&A | | 39.4 % | | 38.7 % | | 34.5 % | | 34.3 % |

| R&D | | 12.1 % | | 13.6 % | | 11.4 % | | 12.6 % |

| Operating income | | 7.2 % | | 15.1 % | | 23.5 % | | 22.5 % |

| Net income | | 8.7 % | | 7.5 % | | 18.0 % | | 17.2 % |

| Income tax rate | | 26.5 % | | 21.0 % | | 23.3 % | | 22.1 % |

| LIVANOVA PLC AND SUBSIDIARIES | | |

| CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - UNAUDITED |

| (In millions, except for per share amounts) | | |

| | | | | |

| | | Nine Months Ended September 30, |

| | | 2026 | | 2025 |

| Net revenue | | $1,146.0 | | $1,027.1 |

| Cost of sales | | 363.5 | | 327.0 |

| Gross profit | | 782.5 | | 700.1 |

| Operating expenses: | | | | |

| Selling, general, and administrative | | 456.6 | | 405.4 |

| Research and development | | 160.0 | | 133.6 |

| Other operating expense | | 46.4 | | 4.2 |

| Operating income | | 119.4 | | 156.8 |

| SNIA environmental liability expense | | — | | (363.8) |

| Interest expense | | (23.4) | | (41.1) |

| Foreign exchange and other income/(expense) | | (3.2) | | (0.3) |

| Income (loss) before income tax | | 92.7 | | (248.4) |

| Income tax (benefit) expense | | (73.5) | | 24.9 |

| Loss from equity method investments | | (1.0) | | — |

| Net income (loss) | | $165.2 | | ($273.4) |

| | | | | |

| Earnings (loss) per share: (1) | | | | |

| Basic | | $3.01 | | ($5.01) |

| Diluted | | $2.93 | | ($5.01) |

| | | | | |

| Weighted average shares outstanding: | | | | |

| Basic | | 54.9 | | 54.5 |

| Diluted | | 56.3 | | 54.5 |

| (1) | For additional details, refer to the computation of basic and diluted earnings (loss) per share further in this news release. |

| * Numbers may not add precisely due to rounding. |

| Adjusted Financial Measures (in millions, except for per share amounts) - Unaudited |

| | | |

| | | Nine Months Ended September 30, |

| | | 2026 | | 2025 |

| Adjusted SG&A | | $401.3 | | $359.9 |

| Adjusted R&D | | 141.8 | | 127.2 |

| Adjusted operating income | | 254.1 | | 222.3 |

| Adjusted net income | | 196.2 | | 166.9 |

| Adjusted diluted earnings per share | | $3.48 | | $3.04 |

| Statistics (as a % of net revenue, except for income tax rate) - Unaudited |

| | | | | |

| | | GAAP Nine Months Ended September 30, | | Adjusted Nine Months Ended September 30, |

| | | 2026 | | 2025 | | 2026 | | 2025 |

| Gross profit | | 68.3 % | | 68.2 % | | 69.6 % | | 69.1 % |

| SG&A | | 39.8 % | | 39.5 % | | 35.0 % | | 35.0 % |

| R&D | | 14.0 % | | 13.0 % | | 12.4 % | | 12.4 % |

| Operating income | | 10.4 % | | 15.3 % | | 22.2 % | | 21.6 % |

| Net income (loss) | | 14.4 % | | (26.6) % | | 17.1 % | | 16.3 % |

| Income tax rate | | (79.2) % | | (10.0) % | | 22.7 % | | 22.7 % |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) |

| | | Non-GAAP Adjustments | |

| Three Months Ended September 30, 2026 | GAAP Financial Measures | Depreciation and Amortization Expense (1) | Financing Related Items (2) | Contingent Consideration (3) | Certain Legal & Regulatory Costs (4) | Share-based Compensation Costs (5) | Certain Tax Adjustments (6) | Adjusted Financial Measures |

| Cost of sales | $128.1 | | ($3.7 | ) | $— | | ($3.3 | ) | $— | | ($0.6 | ) | $— | | $120.5 | |

| Gross profit percent | 67.4 | % | 0.9 | % | — | % | 0.8 | % | — | % | 0.2 | % | — | % | 69.3 | % |

| Selling, general, and administrative | 154.9 | | (2.6 | ) | — | | — | | (5.6 | ) | (11.1 | ) | — | | 135.7 | |

| Selling, general, and administrative as a percent of net revenue | 39.4 | % | (0.7 | )% | — | % | — | % | (1.4 | )% | (2.8 | )% | — | % | 34.5 | % |

| Research and development | 47.7 | | — | | — | | — | | (0.2 | ) | (2.9 | ) | — | | 44.7 | |

| Research and development as a percent of net revenue | 12.1 | % | — | % | — | % | — | % | (0.1 | )% | (0.7 | )% | — | % | 11.4 | % |

| Other operating expense | 34.0 | | — | | — | | — | | (34.0 | ) | — | | — | | — | |

| Operating income | 28.4 | | 6.2 | | — | | 3.3 | | 39.8 | | 14.6 | | — | | 92.3 | |

| Operating margin percent | 7.2 | % | 1.6 | % | — | % | 0.8 | % | 10.1 | % | 3.7 | % | — | % | 23.5 | % |

| Net income | 34.3 | | 6.2 | | (18.3 | ) | 3.3 | | 39.8 | | 14.6 | | (9.1 | ) | 70.7 | |

| Net income as a percent of net revenue | 8.7 | % | 1.6 | % | (4.7 | )% | 0.8 | % | 10.1 | % | 3.7 | % | (2.3 | )% | 18.0 | % |

| Diluted earnings per share | $0.11 | | $0.11 | | $0.17 | | $0.06 | | $0.69 | | $0.25 | | ($0.16 | ) | $1.23 | |

| GAAP results for the three months ended September 30, 2026 include: |

| (1) | Depreciation and amortization associated with purchase price accounting |

| (2) | Mark-to-market adjustments for the 2029 Notes embedded and capped call derivatives, and non-cash interest expense |

| (3) | Remeasurement of contingent consideration related to the ImThera acquisition |

| (4) | 3T Heater-Cooler litigation provision, and legal expenses primarily related to 3T Heater-Cooler defense |

| (5) | Non-cash expenses associated with share-based compensation costs |

| (6) | The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments |

| • Numbers may not add precisely due to rounding. |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) |

| | | Non-GAAP Adjustments | |

| Three Months Ended September 30, 2025 | GAAP Financial Measures | Depreciation and Amortization Expense (1) | Investment Related Items (2) | Financing Related Items (3) | Contingent Consideration (4) | Certain Legal & Regulatory Costs (5) | Share-based Compensation Costs (6) | Certain Tax Adjustments (7) | Adjusted Financial Measures |

| Cost of sales | $112.9 | | ($1.9 | ) | $— | | $— | | ($1.0 | ) | $— | | ($0.5 | ) | $— | | $109.5 | |

| Gross profit percent | 68.4 | % | 0.5 | % | — | % | — | % | 0.3 | % | — | % | 0.1 | % | — | % | 69.4 | % |

| Selling, general, and administrative | 138.5 | | (2.6 | ) | — | | — | | — | | (6.2 | ) | (6.8 | ) | — | | 122.8 | |

| Selling, general, and administrative as a percent of net revenue | 38.7 | % | (0.7 | )% | — | % | — | % | — | % | (1.7 | )% | (1.9 | )% | — | % | 34.3 | % |

| Research and development | 48.6 | | — | | — | | — | | (0.8 | ) | (0.2 | ) | (2.6 | ) | — | | 45.0 | |

| Research and development as a percent of net revenue | 13.6 | % | — | % | — | % | — | % | (0.2 | )% | (0.1 | )% | (0.7 | )% | — | % | 12.6 | % |

| Other operating expense | 3.7 | | — | | — | | — | | — | | (3.7 | ) | — | | — | | — | |

| Operating income | 54.0 | | 4.5 | | — | | — | | 1.8 | | 10.2 | | 9.9 | | — | | 80.4 | |

| Operating margin percent | 15.1 | % | 1.2 | % | — | % | — | % | 0.5 | % | 2.9 | % | 2.8 | % | — | % | 22.5 | % |

| Net income | 26.8 | | 4.5 | | 1.0 | | 15.9 | | 1.8 | | 12.0 | | 9.9 | | (10.4 | ) | 61.4 | |

| Net income as a percent of net revenue | 7.5 | % | 1.2 | % | 0.3 | % | 4.5 | % | 0.5 | % | 3.3 | % | 2.8 | % | (2.9 | )% | 17.2 | % |

| Diluted earnings per share | $0.49 | | $0.08 | | $0.02 | | $0.29 | | $0.03 | | $0.22 | | $0.18 | | ($0.19 | ) | $1.11 | |

| GAAP results for the three months ended September 30, 2025 include: |

| (1) | Depreciation and amortization associated with purchase price accounting |

| (2) | Impairment of investment in Highlife S.A.S. |

| (3) | Mark-to-market adjustments for the 2025 and 2029 Notes embedded and capped call derivatives, and non-cash interest expense |

| (4) | Remeasurement of contingent consideration related to the ImThera acquisition |

| (5) | Legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater-Cooler litigation provision, and SNIA environmental liability |

| (6) | Non-cash expenses associated with share-based compensation costs |

| (7) | The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments |

| • Numbers may not add precisely due to rounding. |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) |

| | | Non-GAAP Adjustments | |

| Nine Months Ended September 30, 2026 | GAAP Financial Measures | Depreciation and Amortization Expense (1) | Investment Related Items (2) | Financing Related Items (3) | Contingent Consideration (4) | Certain Legal & Regulatory Costs (5) | Share-based Compensation Costs (6) | Certain Tax Adjustments (7) | Adjusted Financial Measures |

| Cost of sales | $363.5 | | ($9.4 | ) | $— | | $— | | ($3.3 | ) | $— | | ($1.9 | ) | $— | | $348.8 | |

| Gross profit percent | 68.3 | % | 0.8 | % | — | % | — | % | 0.3 | % | — | % | 0.2 | % | — | % | 69.6 | % |

| Selling, general, and administrative | 456.6 | | (7.8 | ) | — | | — | | — | | (17.3 | ) | (30.2 | ) | — | | 401.3 | |

| Selling, general, and administrative as a percent of net revenue | 39.8 | % | (0.7 | )% | — | % | — | % | — | % | (1.5 | )% | (2.6 | )% | — | % | 35.0 | % |

| Research and development | 160.0 | | 0.1 | | — | | — | | (10.4 | ) | (0.4 | ) | (7.6 | ) | — | | 141.8 | |

| Research and development as a percent of net revenue | 14.0 | % | — | % | — | % | — | % | (0.9 | )% | — | % | (0.7 | )% | — | % | 12.4 | % |

| Other operating expense | 46.4 | | — | | — | | — | | — | | (46.4 | ) | — | | — | | — | |

| Operating income | 119.4 | | 17.1 | | — | | — | | 13.8 | | 64.2 | | 39.7 | | — | | 254.1 | |

| Operating margin percent | 10.4 | % | 1.5 | % | — | % | — | % | 1.2 | % | 5.6 | % | 3.5 | % | — | % | 22.2 | % |

| Net income | 165.2 | | 17.1 | | (12.7 | ) | 40.5 | | 13.8 | | 64.2 | | 39.7 | | (131.5 | ) | 196.2 | |

| Net income as a percent of net revenue | 14.4 | % | 1.5 | % | (1.1 | )% | 3.5 | % | 1.2 | % | 5.6 | % | 3.5 | % | (11.5 | )% | 17.1 | % |

| Diluted earnings per share | $2.93 | | $0.30 | | ($0.23 | ) | $0.72 | | $0.24 | | $1.14 | | $0.71 | | ($2.33 | ) | $3.48 | |

| GAAP results for the nine months ended September 30, 2026 include: |

| (1) | Depreciation and amortization associated with purchase price accounting |

| (2) | Gain on sale of investment, partially offset by impairment of investment without readily determinable fair value |

| (3) | Mark-to-market adjustments for the 2029 Notes embedded and capped call derivatives, non-cash interest expense, and loss on debt extinguishment |

| (4) | Remeasurement of contingent consideration related to the ImThera acquisition |

| (5) | Legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater-Cooler litigation provision, Saluggia site remediation provision, and Medical Device Regulation ("MDR") costs |

| (6) | Non-cash expenses associated with share-based compensation costs |

| (7) | The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments |

| • Numbers may not add precisely due to rounding. |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions, except for per share amounts) |

| | | Non-GAAP Adjustments | |

| Nine Months Ended September 30, 2025 | GAAP Financial Measures | Restructuring Expense (1) | Depreciation and Amortization Expense (2) | Investment Related Items (3) | Financing Related Items (4) | Contingent Consideration (5) | Certain Legal & Regulatory Costs (6) | Share-based Compensation Costs (7) | Certain Tax Adjustments (8) | Adjusted Financial Measures |

| Cost of sales | $327.0 | | $— | | ($5.3 | ) | $— | | $— | | ($2.8 | ) | $— | | ($1.2 | ) | $— | | $317.7 | |

| Gross profit percent | 68.2 | % | — | % | 0.5 | % | — | % | — | % | 0.3 | % | — | % | 0.1 | % | — | % | 69.1 | % |

| Selling, general, and administrative | 405.4 | | — | | (7.6 | ) | — | | — | | — | | (17.5 | ) | (20.4 | ) | — | | 359.9 | |

| Selling, general, and administrative as a percent of net revenue | 39.5 | % | — | % | (0.7 | )% | — | % | — | % | — | % | (1.7 | )% | (2.0 | )% | — | % | 35.0 | % |

| Research and development | 133.6 | | — | | 0.1 | | — | | — | | (2.7 | ) | 1.4 | | (5.3 | ) | — | | 127.2 | |

| Research and development as a percent of net revenue | 13.0 | % | — | % | — | % | — | % | — | % | (0.3 | )% | 0.1 | % | (0.5 | )% | — | % | 12.4 | % |

| Other operating expense | 4.2 | | 0.2 | | — | | — | | — | | — | | (4.4 | ) | — | | — | | — | |

| Operating income | 156.8 | | (0.2 | ) | 12.8 | | — | | — | | 5.5 | | 20.5 | | 26.9 | | — | | 222.3 | |

| Operating margin percent | 15.3 | % | — | % | 1.2 | % | — | % | — | % | 0.5 | % | 2.0 | % | 2.6 | % | — | % | 21.6 | % |

| Net (loss) income | (273.4 | ) | (0.2 | ) | 12.8 | | 4.2 | | 30.9 | | 5.5 | | 384.4 | | 26.9 | | (24.1 | ) | 166.9 | |

| Net (loss) income as a percent of net revenue | (26.6 | )% | — | % | 1.2 | % | 0.4 | % | 3.0 | % | 0.5 | % | 37.4 | % | 2.6 | % | (2.3 | )% | 16.3 | % |

| Diluted (loss) earnings per share (9) | ($5.01 | ) | $— | | $0.23 | | $0.08 | | $0.56 | | $0.10 | | $7.01 | | $0.49 | | ($0.44 | ) | $3.04 | |

| GAAP results for the nine months ended September 30, 2025 include: |

| (1) | Restructuring expense related to organizational changes |

| (2) | Depreciation and amortization associated with purchase price accounting |

| (3) | Loss on investment revaluation of Ceribell, Inc. and impairment of investment in Highlife S.A.S. |

| (4) | Mark-to-market adjustments for the 2025 and 2029 Notes embedded and capped call derivatives, interest expense on the Term Facilities, non-cash interest expense on the 2025 and 2029 Notes and Revolving Credit Facility, loss on debt extinguishment, and interest income on the collateral for the SNIA litigation guarantee and delayed draw on Term Facilities |

| (5) | Remeasurement of contingent consideration related to the ImThera acquisition |

| (6) | SNIA environmental liability, legal expenses primarily related to 3T Heater-Cooler defense, MDR costs, 3T Heater-Cooler litigation provision, and R&D tax incentive |

| (7) | Non-cash expenses associated with share-based compensation costs |

| (8) | The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments |

| (9) | The denominator used to calculate the impact of non-GAAP adjustments on a per share basis and adjusted diluted earnings per share includes dilution from LivaNova's share-based compensation awards that was excluded from the calculation of GAAP diluted loss per share because the effect would have been anti-dilutive. See the reconciliation of GAAP diluted weighted average shares outstanding, used in the computation of GAAP diluted loss per share, to adjusted diluted weighted average shares outstanding, used in the computation of adjusted diluted earnings per share, at the end of this news release. |

| • Numbers may not add precisely due to rounding. |

| LIVANOVA PLC AND SUBSIDIARIES |

| CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED |

| (In millions) |

| | | September 30, 2026 | | December 31, 2025 |

| ASSETS | | | | |

| Current Assets: | | | | |

| Cash and cash equivalents | | $563.5 | | $635.6 |

| Accounts receivable, net of allowance | | 236.4 | | 216.0 |

| Inventories | | 177.9 | | 164.7 |

| Prepaid and refundable taxes | | 46.3 | | 48.6 |

| Prepaid expenses and other current assets | | 58.9 | | 36.8 |

| Total Current Assets | | 1,082.8 | | 1,101.6 |

| Property, plant, and equipment, net | | 293.3 | | 242.6 |

| Goodwill | | 778.8 | | 792.8 |

| Intangible assets, net | | 210.7 | | 230.0 |

| Operating lease assets | | 56.7 | | 55.5 |

| Investments | | 16.8 | | 20.3 |

| Deferred tax assets | | 194.5 | | 111.0 |

| Long-term derivative assets | | 52.6 | | 36.6 |

| Other assets | | 26.9 | | 15.7 |

| Total Assets | | $2,713.1 | | $2,606.1 |

| LIABILITIES AND SHAREHOLDERS’ EQUITY | | | | |

| Current Liabilities: | | | | |

| Current debt obligations | | $3.9 | | $31.5 |

| Accounts payable | | 106.9 | | 97.2 |

| Accrued liabilities and other | | 128.9 | | 107.1 |

| SNIA environmental liability | | 383.6 | | 396.2 |

| Current contingent consideration | | — | | 50.0 |

| Taxes payable | | 28.9 | | 33.1 |

| Accrued employee compensation and related benefits | | 87.9 | | 92.9 |

| Total Current Liabilities | | 740.2 | | 808.1 |

| Long-term debt obligations | | 295.2 | | 345.2 |

| Long-term contingent consideration | | 45.4 | | 42.0 |

| Deferred tax liabilities | | 7.7 | | 9.6 |

| Long-term operating lease liabilities | | 48.8 | | 48.3 |

| Long-term employee compensation and related benefits | | 13.9 | | 13.6 |

| Long-term derivative liabilities | | 124.8 | | 83.9 |

| Other long-term liabilities | | 65.1 | | 55.4 |

| Total Liabilities | | 1,341.1 | | 1,406.1 |

| Total Shareholders’ Equity | | 1,372.1 | | 1,200.0 |

| Total Liabilities and Shareholders’ Equity | | $2,713.1 | | $2,606.1 |

| * Numbers may not add precisely due to rounding. |

| LIVANOVA PLC AND SUBSIDIARIES | | |

| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED | | | | |

| (In millions) | | Nine Months Ended September 30, |

| | | 2026 | | | 2025 | |

| Operating Activities: | | | | |

| Net income (loss) | | $165.2 | | | ($273.4 | ) |

| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | | | | |

| Deferred income tax (benefit) expense | | (86.9 | ) | | 4.1 | |

| Share-based compensation | | 39.7 | | | 26.9 | |

| Remeasurement of derivative instruments | | 29.4 | | | (17.0 | ) |

| Depreciation | | 26.2 | | | 21.0 | |

| Amortization of intangible assets | | 17.6 | | | 13.2 | |

| Amortization of debt issuance costs | | 14.8 | | | 17.3 | |

| Remeasurement of contingent consideration to fair value | | 13.8 | | | 5.5 | |

| Gain on sale of investment | | (13.6 | ) | | — | |

| Amortization of operating lease assets | | 7.8 | | | 10.7 | |

| Impairment of investment | | 1.1 | | | 1.1 | |

| Loss on debt extinguishment | | 0.9 | | | 2.7 | |

| Loss on investment revaluation - Ceribell, Inc. | | — | | | 3.6 | |

| Other, net | | 0.3 | | | 2.4 | |

| Changes in operating assets and liabilities: | | | | |

| Accounts receivable, net | | (22.5 | ) | | (5.8 | ) |

| Inventories | | (15.4 | ) | | (8.1 | ) |

| Other current and non-current assets | | (25.8 | ) | | 50.6 | |

| Accounts payable and accrued current and non-current liabilities | | (14.7 | ) | | (36.1 | ) |

| Taxes payable | | (11.3 | ) | | (13.6 | ) |

| Litigation provision liability | | 29.0 | | | 3.0 | |

| SNIA environmental liability | | — | | | 363.8 | |

| Net cash provided by operating activities | | 155.5 | | | 171.9 | |

| Investing Activities: | | | | |

| Purchases of property, plant, and equipment | | (76.6 | ) | | (48.8 | ) |

| Proceeds from investments | | 9.1 | | | 6.5 | |

| Purchases of investments | | (2.1 | ) | | — | |

| Other, net | | 0.1 | | | (0.4 | ) |

| Net cash used in investing activities | | (69.6 | ) | | (42.7 | ) |

| Financing Activities: | | | | |

| Repayment of long-term debt obligations | | (95.9 | ) | | (216.8 | ) |

| Payment of contingent consideration | | (50.4 | ) | | — | |

| Shares repurchased from employees for minimum tax withholding | | (11.7 | ) | | (3.6 | ) |

| Other, net | | 4.5 | | | (2.3 | ) |

| Net cash used in financing activities | | (153.6 | ) | | (222.8 | ) |

| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | | (4.3 | ) | | 16.0 | |

| Net decrease in cash, cash equivalents, and restricted cash | | (72.1 | ) | | (77.5 | ) |

| Cash, cash equivalents, and restricted cash at beginning of period | | 635.6 | | | 723.6 | |

| Cash and cash equivalents at end of period | | $563.5 | | | $646.1 | |

| * Numbers may not add precisely due to rounding. |

| COMPUTATION OF BASIC AND DILUTED EARNINGS (LOSS) PER SHARE - UNAUDITED (In millions, except for per share amounts) |

| | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | 2025 | | 2026 | | 2025 | |

| Numerator: | | | | | | | | |

| Net income (loss) - basic | | $34.3 | | | $26.8 | | $165.2 | | ($273.4 | ) |

| Less: Gain on 2029 Notes conversion option change in fair value, net of tax (1) | | (28.2 | ) | | — | | — | | — | |

| Net income (loss) - diluted | | $6.1 | | | $26.8 | | $165.2 | | ($273.4 | ) |

| | | | | | | | | |

| Denominator: | | | | | | | | |

| Basic weighted average shares outstanding | | 55.1 | | | 54.6 | | 54.9 | | 54.5 | |

| Add: Dilutive effect of share-based compensation | | 1.6 | | | 0.5 | | 1.4 | | — | |

| Add: Dilutive effect of convertible debt instrument (1) | | 0.6 | | | — | | — | | — | |

| Diluted weighted average shares outstanding | | 57.4 | | | 55.2 | | 56.3 | | 54.5 | |

| | | | | | | | | |

| Earnings (Loss) Per Share: | | | | | | | | |

| Basic | | $0.62 | | | $0.49 | | $3.01 | | ($5.01 | ) |

| Diluted | | $0.11 | | | $0.49 | | $2.93 | | ($5.01 | ) |

| (1) | For the three months ended September 30, 2025, and for the nine months ended September 30, 2026 and 2025, the 2029 Notes were outstanding and potentially dilutive securities but were excluded from the computation of diluted earnings (loss) per share because their effect would have been anti-dilutive under the if-converted method. |

| * Numbers may not add precisely due to rounding. |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions) |

| | | Three Months Ended September 30, |

| | | 2026 | | 2025 |

| | | GAAP Financial Measures | | Certain Tax Adjustments | | Adjusted Financial Measures | | GAAP Financial Measures | | Certain Tax Adjustments | | Adjusted Financial Measures |

| Income before income tax | | $46.8 | | | $— | | | $92.3 | | | $33.9 | | | $— | | | $78.9 | |

| Income tax expense | | 12.4 | | | 9.1 | | | 21.5 | | | 7.1 | | | 10.4 | | | 17.5 | |

| Loss from equity method investments | | (0.1 | ) | | — | | | (0.1 | ) | | — | | | — | | | — | |

| Net income | | $34.3 | | | ($9.1 | ) | | $70.7 | | | $26.8 | | | ($10.4 | ) | | $61.4 | |

| Income tax rate | | 26.5 | % | | | | 23.3 | % | | 21.0 | % | | | | 22.1 | % |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions) |

| | | Nine Months Ended September 30, |

| | | 2026 | | 2025 |

| | | GAAP Financial Measures | | Certain Tax Adjustments | | Adjusted Financial Measures | | GAAP Financial Measures | | Certain Tax Adjustments | | Adjusted Financial Measures |

| Income (loss) before income tax | | $92.7 | | | $— | | | $255.3 | | | ($248.4 | ) | | $— | | | $215.9 | |

| Income tax (benefit) expense | | (73.5 | ) | | 131.5 | | | 58.0 | | | 24.9 | | | 24.1 | | | 49.0 | |

| Loss from equity method investments | | (1.0 | ) | | — | | | (1.0 | ) | | — | | | — | | | — | |

| Net income (loss) | | $165.2 | | | ($131.5 | ) | | $196.2 | | | ($273.4 | ) | | ($24.1 | ) | | $166.9 | |

| Income tax rate | | (79.2 | )% | | | | 22.7 | % | | (10.0 | )% | | | | 22.7 | % |

| * Numbers may not add precisely due to rounding. |

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions) | | |

| | | Three Months Ended September 30, 2026 |

| Net cash provided by operating activities | | $73.7 | |

| Less: Purchases of property, plant, and equipment | | (30.8 | ) |

| Add: 3T Heater-Cooler litigation payments | | 12.9 | |

| Adjusted free cash flow | | $55.8 | |

| * Numbers may not add precisely due to rounding. |

The following table presents the reconciliation of GAAP diluted weighted average shares outstanding, used in the computation of GAAP diluted loss per share, to adjusted diluted weighted average shares outstanding, used in the computation of adjusted diluted earnings per share:

| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (In millions) | | |

| | | Nine Months Ended September 30, 2025 |

| GAAP diluted weighted average shares outstanding | | 54.5 |

| Add: Effects of share-based compensation instruments | | 0.3 |

| Adjusted diluted weighted average shares outstanding | | 54.8 |

| * Numbers may not add precisely due to rounding. |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104266833/en/

Briana Gotlin Vice President, Investor Relations Phone: +1 281 895 2382 e-mail: [email protected]

Source: LivaNova PLC

Top

Company Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. Learn More About Our Cookie Policy

Allow All

Manage Consent Preferences

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

View Vendor Details

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

View Vendor Details

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

View Vendor Details

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

View Vendor Details

Vendors List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

October 23, 2026

PDF Version 169.9 KB

– CORE-VNS is the largest prospective, multinational observational study evaluating contemporary VNS Therapy devices in people with Drug-Resistant Epilepsy – Demonstrated 76% median reduction in seizure frequency and a durable clinical benefit – Data also showed improvements in rescue medication use, healthcare resource utilization, seizure severity, and quality of life

GLOUCESTER, England--(BUSINESS WIRE)--Oct. 23, 2026--

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 reports findings from the full international CORE-VNS cohort, providing one of the most extensive evaluations of long-term outcomes associated with contemporary VNS Therapy in people with DRE.

Conducted across 61 sites in 16 countries, CORE-VNS demonstrated favorable long-term outcomes and clinically meaningful effectiveness of adjunctive VNS Therapy in both children and adults with DRE. Significant benefits were observed as early as three months after implantation and sustained through 36 months of follow-up.

Among participants with available 36-month follow-up data, median seizure frequency was reduced by 76% from baseline. Within this same participant population, 64% achieved at least a 50% reduction in seizure frequency, including nearly half who experienced an 80% or greater reduction in seizures. Benefits extended beyond seizure reduction, including improvements in rescue medication use, healthcare resource utilization, seizure severity, and quality of life. Specifically, at 36 months:

  • 16% (64/392; 95% confidence interval [CI] 13.3%–19.7%) achieved complete seizure freedom

  • 28% (108/392; 95% CI 23.9%–31.5%) had a 100% reduction in the seizure types present at baseline

  • 45% (174/391) reported improved quality of life

  • 73% reduction in seizure-related hospitalizations compared to baseline

Importantly, investigators found that therapeutic benefit was durable throughout follow-up, with increasing proportions of participants progressing into higher response categories over time. Seizure freedom increased steadily over the course of the study, and most participants who responded to VNS Therapy either maintained or improved their outcomes at subsequent visits. Regression to lower response categories was uncommon.

Long-Term Benefits Sustained Through 36 Months

“This study provides compelling, real-world evidence supporting the long-term effectiveness and safety of modern VNS Therapy for people living with drug-resistant epilepsy,” said Arjune Sen, Professor of Global Epilepsy at The University of Oxford, Consultant Neurologist at Oxford University Hospitals NHS Foundation Trust, and coordinating investigator for the CORE-VNS study. “We observed meaningful clinical benefits as early as three months after implantation, and those benefits endured throughout the study period. Beyond reducing seizure frequency, the study demonstrated improvements in healthcare utilization and reductions in seizure severity. The CORE-VNS findings underscore the important role VNS Therapy can play in the long-term management of drug-resistant epilepsy and highlight the importance of timely referral to comprehensive epilepsy centers for evaluation once drug resistance has been established.”

Results Observed Across the Full CORE-VNS Cohort

The published analysis included 531 participants (of the more than 800 total in the broader study) receiving their first VNS Therapy implant, of whom 426 completed 36 months of follow-up, representing an 80% retention rate. The data also demonstrated significant reductions in seizure severity and post-ictal severity across all seizure types, with no new safety concerns identified.

Epilepsy affects over 50 million people worldwide,2, 3 and approximately one-third of people living with epilepsy will develop DRE despite treatment with anti-seizure medications.4-6 Although current practice guidelines recommend referral to specialized epilepsy centers once drug resistance has been established, many patients experience significant delays before being evaluated for advanced treatment options.

“The findings published in Neuromodulation demonstrate not only a 76% median reduction in seizure frequency at three years but also meaningful benefits across multiple measures important to patients, caregivers, and healthcare systems,” said Stephanie Bolton, President, Global Epilepsy at LivaNova. “Most encouragingly, the study showed that benefits from VNS Therapy emerged early and continued to improve over time, reinforcing its important role in the long-term management of Drug-Resistant Epilepsy.”

Benefits Extended Beyond Seizure Reduction

Beyond improvements in seizure outcomes, this analysis showed meaningful benefits across several aspects of disease management and patient well-being, including reduced seizure and post-ictal severity, changes in rescue medication use, improved quality of life, favorable safety outcomes, and reduced healthcare resource utilization.

The study also demonstrated substantial reductions in healthcare resource utilization. The percentage of participants reporting seizure-related emergency department visits decreased from 32% at baseline to 15% at 36 months, while seizure-related hospitalizations declined from 27% to 7%, representing a 73% reduction.

References

About CORE-VNS

CORE-VNS is a real-world, long-term, open-label study focused on the outcomes of VNS Therapy™ in people diagnosed with drug-resistant epilepsy (DRE). Enrolling more than 800 people from 61 sites worldwide, the study is the most comprehensive assessment of the effectiveness of VNS Therapy to date and provides modern insights into the global use of VNS Therapy in the management and control of seizures. As an observational study, outcomes reflect real-world clinical practice and should be interpreted within the context of the study design.

Adverse events in the CORE-VNS study were typical of those reported in the product labeling and experienced following placement of a VNS Therapy device. The most commonly reported (>5%) adverse events overall included respiratory, thoracic, and mediastinal disorders (dysphonia, dyspnea, cough) and general disorders/administration site conditions. See important safety information at VNSTherapy.com/safety.

About VNS Therapy™ for Epilepsy

VNS Therapy™ is approved and clinically proven safe and effective as an adjunctive therapy to reduce the frequency of seizures in adults and children with Drug-Resistant Epilepsy and focal onset seizures. It is a unique treatment approach developed for people with Drug-Resistant Epilepsy—a condition that affects approximately one in three people with epilepsy. Unlike some other surgical treatment options for people with Drug-Resistant Epilepsy, VNS Therapy implantation generally involves a day case procedure, with many completed in outpatient settings, and does not require penetration of the skull. Outside the United States, the VNS Therapy indications for use may vary. For more information, including indications, contraindications, warnings, and precautions, please visit VNSTherapy.com/safety.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. With its registered office in the United Kingdom, approximately 3,300 employees, and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding clinical research and the treatment of Drug-Resistant Epilepsy with VNS Therapy™. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261023479534/en/

LivaNova Investor Relations and Media Contacts +1 281-895-2382

Briana GotlinVP, Investor Relations [email protected]

Jim MasilakDirector, External Communications [email protected]

Source: LivaNova PLC

Top

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. Learn More About Our Cookie Policy

Allow All

Manage Consent Preferences

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

View Vendor Details‎

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

View Vendor Details‎

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

View Vendor Details‎

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

View Vendor Details‎

Back

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

  • View Cookies

  • Name

cookie name

Reject All

October 21, 2026

PDF Version 103.7 KB

GLOUCESTER, England--(BUSINESS WIRE)--Oct. 21, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that members of the Company’s Executive Leadership Team will provide general business updates during fireside chats at the four following November healthcare conferences:

  • UBS Global Healthcare Conference on Mon., Nov. 9, from 11-11:35 a.m. EST in Palm Beach, Fla.

  • 8th Annual Wolfe Research Healthcare Conference on Tues., Nov. 10, from 9:20-9:50 a.m. EST in New York City

  • Stifel Healthcare Conference 2026 on Wed., Nov. 11, from 9:20-9:50 a.m. EST in New York City

  • Jefferies Global Healthcare Conference on Tues., Nov. 17, from 10-10:25 a.m. GMT (5-5:25 a.m. EST) in London

The discussions will be available to all interested parties who register to attend the webcasts, which are accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper webcast setup. Replays will be available on the LivaNova website within 24 hours after the live presentation.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience with a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. With its registered office in the United Kingdom, approximately 3,300 employees, and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021927332/en/

LivaNova Investor Relations and Media Contacts

+1 281-895-2382 Briana Gotlin VP, Investor Relations [email protected] Jim Masilak Director, External Communications [email protected]

Source: LivaNova

Top

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. Learn More About Our Cookie Policy

Allow All

Manage Consent Preferences

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

View Vendor Details‎

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

View Vendor Details‎

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

View Vendor Details‎

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

View Vendor Details‎

Back

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

  • View Cookies

  • Name

cookie name

Reject All

Prompts

LivaNova PLC (ticker LIVN), listed in United States.

Company History

Date Change Detail
May 15, 2015 Renamed Sand Holdco Plc → LIVANOVA PLC

ETFs Holding LivaNova PLC

ETF Weight in ETF Shares Market value As of
LFSC 6.61% 104,627 $ 8.35M Aug 31, 2026
SPIT 3.16% 13,452 $ 1.074M Aug 31, 2026
JPSV 1.57% 4,838 $ 444.709K Nov 17, 2026
SCDS 0.51% 504 $ 46.328K Nov 17, 2026
HWSM 0.47% 158 $ 12.992K Jun 30, 2026
AVUV 0.46% 1,603,223 $ 148.202M Nov 16, 2026
AVSC 0.37% 128,546 $ 11.883M Nov 16, 2026
IVSS 0.18% 592 $ 48.68K Jun 30, 2026
AFSM 0.15% 2,432 $ 224.814K Nov 16, 2026
SEIS 0.15% 10,425 $ 857.248K Jun 30, 2026
DFAT 0.14% 496,814 $ 44.813M Nov 12, 2026
DFAS 0.11% 411,902 $ 37.154M Nov 12, 2026
VFMF 0.10% 12,786 $ 1.02M Aug 31, 2026
FSML 0.09% 1,446 $ 118.905K Jun 30, 2026
SMDX 0.08% 1,120 $ 103.533K Nov 17, 2026
AVSU 0.06% 2,892 $ 267.336K Nov 16, 2026
AVUS 0.03% 53,667 $ 4.961M Nov 16, 2026
DFUV 0.03% 43,616 $ 3.934M Nov 12, 2026
MSSM 0.02% 2,049 $ 163.531K Aug 31, 2026
DFAC 0.02% 193,677 $ 17.47M Nov 12, 2026
DXUV 0.02% 13,700 $ 1.236M Nov 12, 2026
DFSV 0.02% 53,287 $ 4.806M Nov 12, 2026
DCOR 0.01% 57,809 $ 5.214M Nov 12, 2026
EBI 0.01% 803 $ 64.087K Aug 31, 2026
DFSU 0.01% 2,266 $ 204.393K Nov 12, 2026
DFAU 0.01% 12,259 $ 1.106M Nov 12, 2026
DFUS 0.01% 16,730 $ 1.509M Nov 12, 2026